| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 128 | 2024 | 965 | 26.940 |
Why?
|
| Brain Ischemia | 55 | 2023 | 398 | 14.000 |
Why?
|
| Ischemic Attack, Transient | 25 | 2023 | 181 | 8.700 |
Why?
|
| Intracranial Arteriosclerosis | 22 | 2023 | 49 | 7.890 |
Why?
|
| Thrombolytic Therapy | 31 | 2023 | 220 | 7.860 |
Why?
|
| Cerebral Hemorrhage | 43 | 2023 | 325 | 7.480 |
Why?
|
| Fibrinolytic Agents | 25 | 2022 | 202 | 6.520 |
Why?
|
| Tissue Plasminogen Activator | 24 | 2023 | 162 | 6.440 |
Why?
|
| Cerebral Infarction | 14 | 2023 | 71 | 4.420 |
Why?
|
| Subarachnoid Hemorrhage | 19 | 2021 | 137 | 3.960 |
Why?
|
| Stroke Rehabilitation | 7 | 2022 | 41 | 3.960 |
Why?
|
| Aged | 144 | 2024 | 18402 | 3.750 |
Why?
|
| Emergency Medical Services | 11 | 2022 | 209 | 3.620 |
Why?
|
| Time-to-Treatment | 8 | 2023 | 97 | 3.480 |
Why?
|
| Anticoagulants | 13 | 2022 | 408 | 3.350 |
Why?
|
| Middle Aged | 144 | 2024 | 25017 | 3.300 |
Why?
|
| Thrombectomy | 12 | 2024 | 158 | 3.250 |
Why?
|
| Male | 168 | 2024 | 40958 | 3.160 |
Why?
|
| Female | 167 | 2024 | 44509 | 2.930 |
Why?
|
| Humans | 243 | 2024 | 86617 | 2.930 |
Why?
|
| Emergency Service, Hospital | 13 | 2023 | 484 | 2.900 |
Why?
|
| Quality of Life | 11 | 2021 | 1583 | 2.890 |
Why?
|
| Atrial Fibrillation | 8 | 2022 | 288 | 2.610 |
Why?
|
| Brain Infarction | 8 | 2021 | 22 | 2.600 |
Why?
|
| Aged, 80 and over | 62 | 2023 | 6501 | 2.540 |
Why?
|
| Platelet Aggregation Inhibitors | 10 | 2023 | 134 | 2.490 |
Why?
|
| Severity of Illness Index | 23 | 2020 | 1801 | 2.480 |
Why?
|
| Patient Transfer | 3 | 2023 | 91 | 2.380 |
Why?
|
| Dementia | 5 | 2022 | 187 | 2.290 |
Why?
|
| Risk Factors | 58 | 2023 | 5417 | 2.260 |
Why?
|
| Disability Evaluation | 10 | 2022 | 136 | 2.260 |
Why?
|
| Cerebrovascular Circulation | 13 | 2021 | 212 | 2.250 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 14 | 2021 | 294 | 2.200 |
Why?
|
| Hospital Mortality | 10 | 2021 | 349 | 2.050 |
Why?
|
| Hospitalization | 12 | 2021 | 849 | 2.030 |
Why?
|
| Reperfusion | 6 | 2024 | 31 | 2.000 |
Why?
|
| Endovascular Procedures | 11 | 2023 | 218 | 1.950 |
Why?
|
| White Matter | 5 | 2023 | 80 | 1.940 |
Why?
|
| Retrospective Studies | 56 | 2024 | 8477 | 1.930 |
Why?
|
| Warfarin | 6 | 2022 | 103 | 1.910 |
Why?
|
| Registries | 22 | 2023 | 702 | 1.900 |
Why?
|
| Neuroimaging | 8 | 2021 | 113 | 1.880 |
Why?
|
| Magnetic Resonance Imaging | 31 | 2023 | 3357 | 1.870 |
Why?
|
| Prospective Studies | 47 | 2021 | 4212 | 1.840 |
Why?
|
| Triage | 7 | 2023 | 108 | 1.830 |
Why?
|
| Cerebral Angiography | 9 | 2021 | 196 | 1.760 |
Why?
|
| Infarction, Middle Cerebral Artery | 7 | 2021 | 35 | 1.760 |
Why?
|
| Venous Thrombosis | 6 | 2023 | 243 | 1.740 |
Why?
|
| Recovery of Function | 8 | 2022 | 272 | 1.720 |
Why?
|
| Hypertension | 12 | 2023 | 1141 | 1.650 |
Why?
|
| Treatment Outcome | 47 | 2024 | 7990 | 1.640 |
Why?
|
| Time Factors | 35 | 2023 | 5209 | 1.630 |
Why?
|
| Cognitive Dysfunction | 7 | 2023 | 132 | 1.510 |
Why?
|
| Predictive Value of Tests | 26 | 2021 | 1673 | 1.500 |
Why?
|
| Cohort Studies | 31 | 2021 | 2767 | 1.490 |
Why?
|
| Natural Language Processing | 2 | 2021 | 37 | 1.450 |
Why?
|
| Chicago | 14 | 2021 | 1379 | 1.430 |
Why?
|
| Intracranial Thrombosis | 5 | 2023 | 27 | 1.310 |
Why?
|
| Cerebral Arteries | 4 | 2017 | 74 | 1.280 |
Why?
|
| Perfusion Imaging | 7 | 2021 | 50 | 1.210 |
Why?
|
| Stents | 8 | 2019 | 377 | 1.200 |
Why?
|
| Adult | 57 | 2024 | 25640 | 1.180 |
Why?
|
| Recurrence | 15 | 2023 | 1139 | 1.140 |
Why?
|
| Magnetic Resonance Angiography | 11 | 2021 | 262 | 1.130 |
Why?
|
| Tomography, X-Ray Computed | 23 | 2023 | 2601 | 1.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 378 | 1.100 |
Why?
|
| Intracranial Hemorrhages | 5 | 2023 | 120 | 1.090 |
Why?
|
| Dihydropyridines | 2 | 2022 | 11 | 1.070 |
Why?
|
| Telemetry | 3 | 2017 | 38 | 1.050 |
Why?
|
| Diagnostic Errors | 4 | 2021 | 160 | 1.010 |
Why?
|
| Blood Pressure | 13 | 2023 | 1143 | 1.000 |
Why?
|
| Hospitals | 5 | 2023 | 294 | 1.000 |
Why?
|
| Seizures | 8 | 2020 | 297 | 0.980 |
Why?
|
| Nervous System Diseases | 3 | 2020 | 151 | 0.970 |
Why?
|
| Brain | 12 | 2020 | 2216 | 0.970 |
Why?
|
| Models, Economic | 3 | 2021 | 60 | 0.960 |
Why?
|
| Acute Disease | 11 | 2023 | 826 | 0.950 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2021 | 54 | 0.950 |
Why?
|
| Public Health | 2 | 2018 | 129 | 0.930 |
Why?
|
| Referral and Consultation | 2 | 2019 | 326 | 0.920 |
Why?
|
| Prognosis | 24 | 2023 | 3675 | 0.900 |
Why?
|
| beta-Alanine | 2 | 2012 | 6 | 0.880 |
Why?
|
| Parathyroid Neoplasms | 1 | 2022 | 55 | 0.870 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2022 | 41 | 0.860 |
Why?
|
| Lipids | 2 | 2021 | 269 | 0.860 |
Why?
|
| Heart Diseases | 3 | 2020 | 290 | 0.840 |
Why?
|
| Neurologists | 2 | 2019 | 6 | 0.840 |
Why?
|
| Vasospasm, Intracranial | 2 | 2012 | 36 | 0.840 |
Why?
|
| Quality Improvement | 4 | 2023 | 428 | 0.840 |
Why?
|
| Antihypertensive Agents | 7 | 2022 | 521 | 0.830 |
Why?
|
| Rehabilitation Centers | 1 | 2021 | 8 | 0.820 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2023 | 107 | 0.820 |
Why?
|
| Glucocorticoids | 1 | 2024 | 352 | 0.810 |
Why?
|
| Neuropsychological Tests | 2 | 2020 | 502 | 0.810 |
Why?
|
| Allied Health Personnel | 1 | 2021 | 19 | 0.800 |
Why?
|
| Cerebral Revascularization | 3 | 2021 | 26 | 0.800 |
Why?
|
| Carotid Artery, Internal, Dissection | 2 | 2014 | 18 | 0.800 |
Why?
|
| Risk Assessment | 17 | 2023 | 2261 | 0.790 |
Why?
|
| Benzimidazoles | 2 | 2012 | 140 | 0.790 |
Why?
|
| Research Report | 1 | 2021 | 44 | 0.780 |
Why?
|
| Cerebrovascular Disorders | 3 | 2020 | 143 | 0.780 |
Why?
|
| Activities of Daily Living | 2 | 2019 | 204 | 0.770 |
Why?
|
| Adenoma | 1 | 2022 | 235 | 0.760 |
Why?
|
| Community Participation | 1 | 2020 | 36 | 0.750 |
Why?
|
| Hospital Costs | 1 | 2021 | 104 | 0.750 |
Why?
|
| Patient Outcome Assessment | 4 | 2017 | 84 | 0.750 |
Why?
|
| Patient Readmission | 4 | 2020 | 329 | 0.730 |
Why?
|
| Machine Learning | 2 | 2019 | 232 | 0.730 |
Why?
|
| Actigraphy | 1 | 2020 | 51 | 0.730 |
Why?
|
| Motor Disorders | 1 | 2019 | 7 | 0.730 |
Why?
|
| International Normalized Ratio | 3 | 2014 | 38 | 0.710 |
Why?
|
| Disabled Persons | 2 | 2019 | 67 | 0.710 |
Why?
|
| Quality Indicators, Health Care | 3 | 2019 | 144 | 0.710 |
Why?
|
| Patient Admission | 3 | 2019 | 112 | 0.710 |
Why?
|
| Venous Thromboembolism | 2 | 2022 | 153 | 0.700 |
Why?
|
| Data Mining | 1 | 2019 | 42 | 0.680 |
Why?
|
| Emergency Medical Service Communication Systems | 2 | 2022 | 6 | 0.670 |
Why?
|
| Hypothermia, Induced | 2 | 2010 | 74 | 0.670 |
Why?
|
| Hematoma, Subdural | 2 | 2020 | 23 | 0.660 |
Why?
|
| Cognition Disorders | 1 | 2020 | 236 | 0.660 |
Why?
|
| Heart | 2 | 2022 | 539 | 0.650 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2018 | 2 | 0.640 |
Why?
|
| Ischemia | 4 | 2019 | 243 | 0.630 |
Why?
|
| Biomarkers | 7 | 2021 | 1718 | 0.630 |
Why?
|
| Logistic Models | 12 | 2018 | 1185 | 0.630 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2009 | 99 | 0.630 |
Why?
|
| Disease Management | 3 | 2017 | 327 | 0.630 |
Why?
|
| Practice Guidelines as Topic | 5 | 2018 | 1034 | 0.620 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 54 | 0.600 |
Why?
|
| Electronic Health Records | 3 | 2019 | 319 | 0.600 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2017 | 19 | 0.600 |
Why?
|
| Constriction, Pathologic | 7 | 2023 | 213 | 0.600 |
Why?
|
| Hemodynamics | 4 | 2020 | 710 | 0.600 |
Why?
|
| Secondary Prevention | 6 | 2021 | 162 | 0.600 |
Why?
|
| Brain Edema | 2 | 2018 | 50 | 0.600 |
Why?
|
| Echocardiography | 3 | 2020 | 911 | 0.600 |
Why?
|
| Transportation of Patients | 2 | 2021 | 32 | 0.600 |
Why?
|
| Carotid Artery, Internal | 4 | 2020 | 69 | 0.590 |
Why?
|
| Arterial Pressure | 1 | 2017 | 38 | 0.590 |
Why?
|
| Aspirin | 4 | 2023 | 156 | 0.590 |
Why?
|
| Longitudinal Studies | 5 | 2020 | 1019 | 0.590 |
Why?
|
| Life Style | 3 | 2020 | 189 | 0.580 |
Why?
|
| Decision Support Techniques | 4 | 2021 | 160 | 0.580 |
Why?
|
| Upper Extremity | 4 | 2022 | 52 | 0.580 |
Why?
|
| Middle Cerebral Artery | 7 | 2021 | 21 | 0.580 |
Why?
|
| Personnel, Hospital | 1 | 2016 | 30 | 0.580 |
Why?
|
| Inservice Training | 1 | 2016 | 38 | 0.580 |
Why?
|
| Follow-Up Studies | 11 | 2022 | 3636 | 0.570 |
Why?
|
| Carotid Stenosis | 3 | 2018 | 112 | 0.560 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 18 | 0.560 |
Why?
|
| Health Promotion | 1 | 2018 | 160 | 0.560 |
Why?
|
| Substance Abuse Detection | 1 | 2015 | 12 | 0.550 |
Why?
|
| United States | 16 | 2023 | 6665 | 0.550 |
Why?
|
| Toxicology | 1 | 2015 | 16 | 0.550 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 379 | 0.550 |
Why?
|
| Brain Mapping | 1 | 2019 | 548 | 0.540 |
Why?
|
| Hospitals, Community | 1 | 2015 | 31 | 0.540 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 2 | 2013 | 12 | 0.530 |
Why?
|
| Magnesium | 4 | 2023 | 177 | 0.530 |
Why?
|
| Odds Ratio | 5 | 2020 | 678 | 0.530 |
Why?
|
| Hemostatics | 3 | 2023 | 56 | 0.530 |
Why?
|
| Informed Consent | 1 | 2018 | 266 | 0.530 |
Why?
|
| Patient Care Team | 2 | 2019 | 280 | 0.520 |
Why?
|
| Hepatic Encephalopathy | 3 | 2020 | 40 | 0.510 |
Why?
|
| Vertebral Artery Dissection | 1 | 2014 | 11 | 0.510 |
Why?
|
| Communication | 2 | 2022 | 441 | 0.510 |
Why?
|
| Prevalence | 8 | 2023 | 1239 | 0.510 |
Why?
|
| Intracranial Aneurysm | 3 | 2020 | 158 | 0.510 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2017 | 344 | 0.500 |
Why?
|
| Remote Consultation | 1 | 2014 | 16 | 0.500 |
Why?
|
| Reproducibility of Results | 8 | 2021 | 2705 | 0.500 |
Why?
|
| Foramen Ovale, Patent | 1 | 2014 | 18 | 0.490 |
Why?
|
| Factor Xa Inhibitors | 1 | 2014 | 22 | 0.490 |
Why?
|
| Basilar Artery | 3 | 2023 | 41 | 0.490 |
Why?
|
| Pelvis | 1 | 2014 | 95 | 0.480 |
Why?
|
| Thrombophilia | 1 | 2013 | 22 | 0.470 |
Why?
|
| Tachycardia | 1 | 2013 | 35 | 0.470 |
Why?
|
| Thiazoles | 1 | 2014 | 131 | 0.470 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2013 | 64 | 0.460 |
Why?
|
| Anticonvulsants | 3 | 2020 | 126 | 0.460 |
Why?
|
| Encephalocele | 1 | 2013 | 24 | 0.450 |
Why?
|
| ROC Curve | 5 | 2020 | 752 | 0.450 |
Why?
|
| Sleep | 1 | 2017 | 444 | 0.450 |
Why?
|
| Early Diagnosis | 4 | 2020 | 131 | 0.440 |
Why?
|
| Injections, Intra-Arterial | 2 | 2013 | 33 | 0.430 |
Why?
|
| Intracranial Hypertension | 1 | 2013 | 48 | 0.430 |
Why?
|
| Pyridines | 1 | 2014 | 310 | 0.420 |
Why?
|
| Nicardipine | 1 | 2011 | 7 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 864 | 0.420 |
Why?
|
| Carotid Artery Diseases | 2 | 2016 | 97 | 0.410 |
Why?
|
| Putaminal Hemorrhage | 1 | 2011 | 1 | 0.410 |
Why?
|
| Health Facilities | 1 | 2011 | 38 | 0.410 |
Why?
|
| Putamen | 1 | 2011 | 13 | 0.410 |
Why?
|
| Angioplasty | 2 | 2010 | 70 | 0.400 |
Why?
|
| Clinical Protocols | 2 | 2009 | 156 | 0.400 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 4 | 2021 | 18 | 0.400 |
Why?
|
| Multivariate Analysis | 7 | 2018 | 999 | 0.400 |
Why?
|
| Hypotension | 1 | 2011 | 70 | 0.400 |
Why?
|
| Paresis | 2 | 2008 | 15 | 0.390 |
Why?
|
| Community Health Centers | 1 | 2012 | 113 | 0.390 |
Why?
|
| Vasodilator Agents | 1 | 2011 | 152 | 0.390 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2010 | 27 | 0.380 |
Why?
|
| Leukoencephalopathies | 2 | 2021 | 15 | 0.380 |
Why?
|
| Vascular Stiffness | 2 | 2020 | 26 | 0.380 |
Why?
|
| Assisted Circulation | 1 | 2010 | 15 | 0.380 |
Why?
|
| Neurosurgical Procedures | 3 | 2021 | 213 | 0.370 |
Why?
|
| Health Education | 1 | 2011 | 101 | 0.370 |
Why?
|
| Intracranial Embolism | 2 | 2020 | 29 | 0.370 |
Why?
|
| Atherosclerosis | 3 | 2021 | 244 | 0.370 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2501 | 0.360 |
Why?
|
| Drug Therapy, Combination | 5 | 2023 | 894 | 0.350 |
Why?
|
| Sex Characteristics | 2 | 2008 | 319 | 0.340 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 858 | 0.340 |
Why?
|
| Kidney Diseases | 1 | 2012 | 418 | 0.330 |
Why?
|
| Gastrostomy | 2 | 2019 | 69 | 0.330 |
Why?
|
| Young Adult | 10 | 2020 | 5974 | 0.320 |
Why?
|
| Dabigatran | 2 | 2022 | 24 | 0.320 |
Why?
|
| Patient Discharge | 4 | 2020 | 300 | 0.320 |
Why?
|
| Ticlopidine | 1 | 2007 | 25 | 0.310 |
Why?
|
| Illinois | 4 | 2019 | 462 | 0.310 |
Why?
|
| Glasgow Coma Scale | 4 | 2018 | 65 | 0.310 |
Why?
|
| Risk Reduction Behavior | 2 | 2021 | 98 | 0.310 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 567 | 0.310 |
Why?
|
| Movement Disorders | 1 | 2007 | 44 | 0.300 |
Why?
|
| Cost-Benefit Analysis | 3 | 2023 | 451 | 0.300 |
Why?
|
| Carotid Arteries | 2 | 2009 | 127 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2020 | 508 | 0.300 |
Why?
|
| Urban Population | 2 | 2021 | 213 | 0.290 |
Why?
|
| Consensus | 3 | 2021 | 335 | 0.290 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 1621 | 0.290 |
Why?
|
| Age Factors | 6 | 2018 | 1849 | 0.280 |
Why?
|
| Hypertensive Encephalopathy | 1 | 2006 | 1 | 0.280 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 1565 | 0.280 |
Why?
|
| Outpatients | 2 | 2017 | 94 | 0.280 |
Why?
|
| Gadolinium | 1 | 2006 | 103 | 0.280 |
Why?
|
| Fever | 2 | 2019 | 125 | 0.280 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2005 | 13 | 0.270 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2005 | 11 | 0.270 |
Why?
|
| Blood Platelets | 2 | 2018 | 149 | 0.270 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2007 | 228 | 0.270 |
Why?
|
| Blood Flow Velocity | 5 | 2020 | 197 | 0.260 |
Why?
|
| Area Under Curve | 2 | 2018 | 334 | 0.260 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2005 | 3 | 0.260 |
Why?
|
| Mycetoma | 1 | 2005 | 3 | 0.260 |
Why?
|
| Medulla Oblongata | 1 | 2006 | 89 | 0.260 |
Why?
|
| Circle of Willis | 2 | 2017 | 5 | 0.260 |
Why?
|
| Inpatients | 4 | 2023 | 297 | 0.250 |
Why?
|
| Calcium Channel Blockers | 2 | 2022 | 203 | 0.250 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2019 | 579 | 0.240 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 581 | 0.240 |
Why?
|
| Clinical Decision-Making | 3 | 2021 | 257 | 0.240 |
Why?
|
| Clinical Trials as Topic | 5 | 2021 | 1169 | 0.240 |
Why?
|
| Neurologic Examination | 3 | 2015 | 118 | 0.240 |
Why?
|
| Length of Stay | 4 | 2021 | 700 | 0.240 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2005 | 206 | 0.230 |
Why?
|
| Patient Selection | 4 | 2020 | 685 | 0.230 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 1991 | 0.230 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2022 | 15 | 0.230 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1685 | 0.220 |
Why?
|
| Comorbidity | 3 | 2015 | 943 | 0.220 |
Why?
|
| Aorta, Thoracic | 3 | 2020 | 165 | 0.220 |
Why?
|
| Emergency Medical Dispatcher | 1 | 2022 | 2 | 0.220 |
Why?
|
| Headache | 4 | 2023 | 73 | 0.210 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2022 | 7 | 0.210 |
Why?
|
| Parathyroidectomy | 1 | 2022 | 78 | 0.210 |
Why?
|
| Computed Tomography Angiography | 2 | 2021 | 131 | 0.210 |
Why?
|
| Databases, Factual | 4 | 2021 | 812 | 0.210 |
Why?
|
| Thorax | 1 | 2022 | 75 | 0.210 |
Why?
|
| Hematoma | 2 | 2023 | 104 | 0.200 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 218 | 0.200 |
Why?
|
| Hospitals, Low-Volume | 1 | 2021 | 18 | 0.200 |
Why?
|
| Guideline Adherence | 1 | 2023 | 223 | 0.200 |
Why?
|
| Disease Progression | 7 | 2019 | 1531 | 0.200 |
Why?
|
| Hospitals, High-Volume | 1 | 2021 | 35 | 0.200 |
Why?
|
| Embolization, Therapeutic | 1 | 2024 | 238 | 0.200 |
Why?
|
| Administration, Oral | 3 | 2022 | 684 | 0.200 |
Why?
|
| Hemostasis | 2 | 2018 | 21 | 0.200 |
Why?
|
| Triglycerides | 1 | 2021 | 232 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 78 | 0.190 |
Why?
|
| Cholesterol, HDL | 1 | 2021 | 165 | 0.190 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2022 | 67 | 0.190 |
Why?
|
| Platelet Function Tests | 2 | 2018 | 11 | 0.190 |
Why?
|
| Hypolipidemic Agents | 1 | 2021 | 102 | 0.190 |
Why?
|
| Alcohol Drinking | 2 | 2020 | 267 | 0.190 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 222 | 0.190 |
Why?
|
| Atrial Remodeling | 1 | 2020 | 17 | 0.190 |
Why?
|
| Thromboembolism | 1 | 2021 | 119 | 0.190 |
Why?
|
| Rural Population | 1 | 2021 | 136 | 0.190 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2020 | 9 | 0.190 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2020 | 5 | 0.190 |
Why?
|
| Physical Therapy Specialty | 1 | 2019 | 1 | 0.180 |
Why?
|
| Hypesthesia | 2 | 2011 | 15 | 0.180 |
Why?
|
| Cerebral Ventricles | 2 | 2013 | 76 | 0.180 |
Why?
|
| Speech Therapy | 1 | 2019 | 8 | 0.180 |
Why?
|
| Self Report | 1 | 2021 | 288 | 0.180 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 46 | 0.180 |
Why?
|
| Financing, Organized | 1 | 2019 | 12 | 0.180 |
Why?
|
| Occupational Therapy | 1 | 2019 | 16 | 0.180 |
Why?
|
| Program Development | 1 | 2020 | 124 | 0.180 |
Why?
|
| Therapeutic Equipoise | 1 | 2019 | 2 | 0.180 |
Why?
|
| Incidence | 6 | 2021 | 1577 | 0.180 |
Why?
|
| Adolescent | 6 | 2023 | 8979 | 0.180 |
Why?
|
| Aorta | 2 | 2020 | 280 | 0.180 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 30 | 0.180 |
Why?
|
| Anisotropy | 1 | 2019 | 62 | 0.180 |
Why?
|
| Diffusion | 1 | 2019 | 93 | 0.180 |
Why?
|
| Sex Factors | 3 | 2020 | 1054 | 0.180 |
Why?
|
| Basal Ganglia Cerebrovascular Disease | 1 | 2019 | 3 | 0.180 |
Why?
|
| Cholesterol | 1 | 2021 | 356 | 0.180 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2022 | 190 | 0.180 |
Why?
|
| Vision Disorders | 2 | 2011 | 75 | 0.170 |
Why?
|
| Parasympathetic Nervous System | 1 | 2019 | 33 | 0.170 |
Why?
|
| Middle East | 1 | 2018 | 17 | 0.170 |
Why?
|
| Hospitals, Public | 1 | 2018 | 15 | 0.170 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2019 | 122 | 0.170 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 763 | 0.170 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 90 | 0.170 |
Why?
|
| Automation | 1 | 2019 | 106 | 0.170 |
Why?
|
| Mentors | 1 | 2019 | 76 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1961 | 0.170 |
Why?
|
| Neuroprotective Agents | 2 | 2017 | 94 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 108 | 0.170 |
Why?
|
| Heart Atria | 1 | 2020 | 250 | 0.160 |
Why?
|
| Frontal Lobe | 1 | 2019 | 130 | 0.160 |
Why?
|
| Preventive Health Services | 1 | 2018 | 37 | 0.160 |
Why?
|
| Postural Balance | 1 | 2018 | 42 | 0.160 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 469 | 0.160 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 153 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2020 | 170 | 0.160 |
Why?
|
| Platelet Activation | 1 | 2018 | 13 | 0.160 |
Why?
|
| Cultural Characteristics | 1 | 2018 | 19 | 0.160 |
Why?
|
| Delirium | 1 | 2018 | 66 | 0.160 |
Why?
|
| Critical Care | 2 | 2013 | 370 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2018 | 24 | 0.160 |
Why?
|
| Neuroprotection | 1 | 2017 | 7 | 0.160 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 103 | 0.160 |
Why?
|
| Pattern Recognition, Automated | 1 | 2019 | 217 | 0.160 |
Why?
|
| Brain Diseases | 1 | 2018 | 180 | 0.150 |
Why?
|
| Anatomic Variation | 1 | 2017 | 3 | 0.150 |
Why?
|
| Ambulances | 1 | 2017 | 15 | 0.150 |
Why?
|
| Neurovascular Coupling | 1 | 2017 | 2 | 0.150 |
Why?
|
| Focus Groups | 1 | 2018 | 155 | 0.150 |
Why?
|
| Urban Health Services | 1 | 2017 | 45 | 0.150 |
Why?
|
| Drug Resistance | 2 | 2008 | 256 | 0.150 |
Why?
|
| New York City | 2 | 2007 | 59 | 0.150 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 297 | 0.150 |
Why?
|
| Moyamoya Disease | 1 | 2017 | 14 | 0.150 |
Why?
|
| Age Distribution | 2 | 2007 | 204 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2019 | 663 | 0.150 |
Why?
|
| Algorithms | 3 | 2017 | 1830 | 0.150 |
Why?
|
| Missouri | 1 | 2016 | 19 | 0.150 |
Why?
|
| Education, Nursing, Continuing | 1 | 2016 | 9 | 0.150 |
Why?
|
| Aortic Diseases | 1 | 2017 | 100 | 0.150 |
Why?
|
| Electrocardiography | 3 | 2020 | 478 | 0.150 |
Why?
|
| Qualitative Research | 1 | 2018 | 256 | 0.140 |
Why?
|
| Research Design | 1 | 2020 | 594 | 0.140 |
Why?
|
| Drug Utilization | 2 | 2020 | 65 | 0.140 |
Why?
|
| Heart Rate | 1 | 2019 | 492 | 0.140 |
Why?
|
| Leptospirosis | 1 | 2016 | 3 | 0.140 |
Why?
|
| Nursing Staff, Hospital | 1 | 2016 | 42 | 0.140 |
Why?
|
| Hemorrhage | 2 | 2015 | 268 | 0.140 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 130 | 0.140 |
Why?
|
| Medical Staff, Hospital | 1 | 2016 | 107 | 0.130 |
Why?
|
| Mobility Limitation | 1 | 2015 | 19 | 0.130 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 107 | 0.130 |
Why?
|
| Monitoring, Ambulatory | 1 | 2015 | 32 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2019 | 375 | 0.130 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 174 | 0.130 |
Why?
|
| Intensive Care Units | 5 | 2019 | 373 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 370 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2016 | 297 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 329 | 0.130 |
Why?
|
| Blood Coagulation Factors | 1 | 2014 | 20 | 0.130 |
Why?
|
| Fibrinogen | 1 | 2014 | 56 | 0.130 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2014 | 12 | 0.120 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 429 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2018 | 1204 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 2 | 2012 | 297 | 0.120 |
Why?
|
| Functional Neuroimaging | 1 | 2013 | 32 | 0.120 |
Why?
|
| Risk | 4 | 2018 | 674 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 827 | 0.120 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2018 | 462 | 0.120 |
Why?
|
| Leukoaraiosis | 1 | 2013 | 3 | 0.110 |
Why?
|
| Troponin I | 1 | 2013 | 27 | 0.110 |
Why?
|
| Arteries | 1 | 2014 | 176 | 0.110 |
Why?
|
| Learning | 1 | 2016 | 280 | 0.110 |
Why?
|
| Factor VIIa | 1 | 2012 | 5 | 0.110 |
Why?
|
| Fatal Outcome | 3 | 2014 | 293 | 0.110 |
Why?
|
| Partial Thromboplastin Time | 1 | 2012 | 18 | 0.110 |
Why?
|
| Plasma | 1 | 2012 | 50 | 0.110 |
Why?
|
| Kidney Function Tests | 1 | 2012 | 123 | 0.110 |
Why?
|
| Coronary Disease | 1 | 2013 | 261 | 0.110 |
Why?
|
| Platelet Count | 1 | 2012 | 92 | 0.110 |
Why?
|
| Blood Coagulation Disorders | 1 | 2013 | 63 | 0.110 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 67 | 0.110 |
Why?
|
| Health Facility Size | 1 | 2011 | 9 | 0.110 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2011 | 34 | 0.100 |
Why?
|
| Blood Coagulation | 1 | 2012 | 91 | 0.100 |
Why?
|
| Angioplasty, Balloon | 2 | 2009 | 95 | 0.100 |
Why?
|
| Decision Trees | 1 | 2011 | 63 | 0.100 |
Why?
|
| Double-Blind Method | 2 | 2014 | 1823 | 0.100 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 244 | 0.100 |
Why?
|
| Certification | 1 | 2011 | 58 | 0.100 |
Why?
|
| Intracranial Pressure | 1 | 2011 | 77 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2011 | 229 | 0.100 |
Why?
|
| Endocarditis | 1 | 2011 | 18 | 0.100 |
Why?
|
| International Classification of Diseases | 1 | 2011 | 69 | 0.100 |
Why?
|
| Vertebral Artery | 1 | 2011 | 23 | 0.100 |
Why?
|
| Speech Disorders | 1 | 2011 | 18 | 0.100 |
Why?
|
| Mass Screening | 1 | 2015 | 617 | 0.100 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2011 | 23 | 0.100 |
Why?
|
| Audiovisual Aids | 1 | 2011 | 7 | 0.100 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2011 | 138 | 0.100 |
Why?
|
| Inflammation | 2 | 2007 | 920 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 384 | 0.100 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2011 | 16 | 0.100 |
Why?
|
| Pulse Wave Analysis | 2 | 2020 | 10 | 0.100 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2010 | 8 | 0.100 |
Why?
|
| Observer Variation | 2 | 2015 | 602 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2012 | 912 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2018 | 2207 | 0.090 |
Why?
|
| Heart Valve Diseases | 1 | 2011 | 109 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1804 | 0.090 |
Why?
|
| Survival Rate | 1 | 2014 | 1860 | 0.090 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 69 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 394 | 0.090 |
Why?
|
| Liver Transplantation | 1 | 2018 | 1268 | 0.090 |
Why?
|
| Drug Synergism | 1 | 2010 | 303 | 0.090 |
Why?
|
| Circadian Rhythm | 1 | 2012 | 303 | 0.090 |
Why?
|
| Vertebrobasilar Insufficiency | 1 | 2009 | 16 | 0.090 |
Why?
|
| Radiography | 1 | 2011 | 813 | 0.090 |
Why?
|
| Language Disorders | 1 | 2008 | 9 | 0.090 |
Why?
|
| Osmolar Concentration | 2 | 2020 | 181 | 0.090 |
Why?
|
| Health Care Surveys | 2 | 2020 | 278 | 0.080 |
Why?
|
| Vertigo | 1 | 2008 | 42 | 0.080 |
Why?
|
| Migraine Disorders | 1 | 2008 | 40 | 0.080 |
Why?
|
| American Heart Association | 2 | 2021 | 92 | 0.080 |
Why?
|
| Emergencies | 1 | 2009 | 113 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2008 | 70 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 916 | 0.080 |
Why?
|
| Bias | 1 | 2008 | 127 | 0.080 |
Why?
|
| North America | 2 | 2018 | 180 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2007 | 173 | 0.080 |
Why?
|
| New York | 1 | 2007 | 69 | 0.080 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2007 | 11 | 0.080 |
Why?
|
| Brain Stem Infarctions | 1 | 2007 | 5 | 0.080 |
Why?
|
| Bacteroides Infections | 1 | 2007 | 8 | 0.070 |
Why?
|
| Meningitis, Bacterial | 1 | 2007 | 13 | 0.070 |
Why?
|
| Cerebellar Diseases | 1 | 2007 | 20 | 0.070 |
Why?
|
| Artifacts | 1 | 2009 | 244 | 0.070 |
Why?
|
| Abdominal Abscess | 1 | 2007 | 22 | 0.070 |
Why?
|
| Ultrasonic Therapy | 1 | 2007 | 32 | 0.070 |
Why?
|
| Causality | 1 | 2007 | 81 | 0.070 |
Why?
|
| Age of Onset | 1 | 2007 | 310 | 0.070 |
Why?
|
| Models, Statistical | 2 | 2007 | 574 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2007 | 121 | 0.070 |
Why?
|
| Students, Medical | 1 | 2011 | 384 | 0.070 |
Why?
|
| Spinal Puncture | 1 | 2005 | 38 | 0.070 |
Why?
|
| Mitosporic Fungi | 1 | 2005 | 3 | 0.070 |
Why?
|
| Brain Stem | 1 | 2006 | 165 | 0.070 |
Why?
|
| Itraconazole | 1 | 2005 | 11 | 0.060 |
Why?
|
| Amphotericin B | 1 | 2005 | 34 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 235 | 0.060 |
Why?
|
| Collagen | 1 | 2006 | 269 | 0.060 |
Why?
|
| Clostridium Infections | 1 | 2007 | 125 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2007 | 695 | 0.060 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 636 | 0.060 |
Why?
|
| Catheterization | 1 | 2005 | 232 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2005 | 117 | 0.060 |
Why?
|
| Radial Artery | 1 | 2024 | 33 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 376 | 0.060 |
Why?
|
| Delayed Diagnosis | 1 | 2023 | 29 | 0.060 |
Why?
|
| Catheters | 1 | 2024 | 74 | 0.060 |
Why?
|
| Animals | 4 | 2016 | 26582 | 0.060 |
Why?
|
| Ventriculostomy | 2 | 2013 | 26 | 0.060 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2022 | 10 | 0.060 |
Why?
|
| Aortic Valve | 2 | 2017 | 222 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2015 | 596 | 0.050 |
Why?
|
| Minimal Clinically Important Difference | 1 | 2022 | 2 | 0.050 |
Why?
|
| Cognition | 2 | 2018 | 570 | 0.050 |
Why?
|
| Eligibility Determination | 1 | 2021 | 31 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2021 | 71 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 48 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1753 | 0.050 |
Why?
|
| Rupture, Spontaneous | 1 | 2020 | 43 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2005 | 307 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 231 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 1056 | 0.050 |
Why?
|
| Specific Gravity | 1 | 2020 | 3 | 0.050 |
Why?
|
| Gait | 1 | 2020 | 80 | 0.050 |
Why?
|
| Occupations | 1 | 2019 | 26 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2021 | 129 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2019 | 35 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2005 | 751 | 0.040 |
Why?
|
| Income | 1 | 2019 | 75 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 133 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 41 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 175 | 0.040 |
Why?
|
| Educational Status | 1 | 2019 | 188 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 22 | 0.040 |
Why?
|
| Medical Order Entry Systems | 1 | 2018 | 25 | 0.040 |
Why?
|
| Smoking Cessation | 1 | 2021 | 230 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2020 | 312 | 0.040 |
Why?
|
| Developing Countries | 1 | 2018 | 71 | 0.040 |
Why?
|
| Clinical Deterioration | 1 | 2018 | 19 | 0.040 |
Why?
|
| Exercise | 1 | 2021 | 315 | 0.040 |
Why?
|
| Asia, Western | 1 | 2017 | 2 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2017 | 197 | 0.040 |
Why?
|
| Emigration and Immigration | 1 | 2017 | 48 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 712 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2017 | 76 | 0.040 |
Why?
|
| Piracetam | 1 | 2016 | 8 | 0.040 |
Why?
|
| Phenytoin | 1 | 2016 | 16 | 0.040 |
Why?
|
| Global Health | 1 | 2018 | 193 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 222 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 153 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 429 | 0.040 |
Why?
|
| Emigrants and Immigrants | 1 | 2017 | 44 | 0.040 |
Why?
|
| Leptospira | 1 | 2016 | 1 | 0.040 |
Why?
|
| Europe | 1 | 2017 | 309 | 0.040 |
Why?
|
| Serogroup | 1 | 2016 | 9 | 0.040 |
Why?
|
| Mechanical Thrombolysis | 1 | 2016 | 15 | 0.040 |
Why?
|
| Craniotomy | 1 | 2016 | 88 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1313 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 50 | 0.030 |
Why?
|
| India | 1 | 2016 | 120 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 69 | 0.030 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2016 | 92 | 0.030 |
Why?
|
| Pregnancy | 1 | 2022 | 2894 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2015 | 62 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 2014 | 37 | 0.030 |
Why?
|
| Brain Waves | 1 | 2014 | 32 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 740 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 927 | 0.030 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2013 | 28 | 0.030 |
Why?
|
| Trauma Severity Indices | 1 | 2013 | 41 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 1721 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 429 | 0.030 |
Why?
|
| Internet | 1 | 2015 | 312 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 751 | 0.030 |
Why?
|
| Oxygen | 1 | 2017 | 726 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2015 | 572 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2014 | 709 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2016 | 2378 | 0.020 |
Why?
|
| Rats | 1 | 2016 | 3990 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 3045 | 0.020 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2011 | 166 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3611 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2013 | 584 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 609 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 183 | 0.020 |
Why?
|
| Glycine Agents | 1 | 2007 | 5 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 1078 | 0.020 |
Why?
|
| Retroperitoneal Space | 1 | 2007 | 38 | 0.020 |
Why?
|
| Coma | 1 | 2007 | 44 | 0.020 |
Why?
|
| Ischemic Preconditioning | 1 | 2005 | 37 | 0.020 |
Why?
|
| Indoles | 1 | 2007 | 318 | 0.020 |
Why?
|
| Child | 1 | 2016 | 6926 | 0.020 |
Why?
|